2022
Serum Neutralizing Antibody Titers 12 Months After Coronavirus Disease 2019 Messenger RNA Vaccination: Correlation to Clinical Variables in an Adult, US Population
Zhao M, Slotkin R, Sheth AH, Pischel L, Kyriakides TC, Emu B, McNamara C, Shi Q, Delgobbo J, Xu J, Marhoffer E, Mercer-Falkoff A, Holleck J, Ardito D, Sutton RE, Gupta S. Serum Neutralizing Antibody Titers 12 Months After Coronavirus Disease 2019 Messenger RNA Vaccination: Correlation to Clinical Variables in an Adult, US Population. Clinical Infectious Diseases 2022, 76: e391-e399. PMID: 35639598, PMCID: PMC9278145, DOI: 10.1093/cid/ciac416.Peer-Reviewed Original ResearchConceptsMonth postboosterRNA vaccinationClinical variablesNeutralization responseEnd-stage renal diseaseBooster dose responsePrimary series vaccinationPrimary vaccine seriesMultiple clinical factorsSystemic steroid useDoses of vaccinePrior COVID-19Maximal inhibitory concentration valuesHalf maximal inhibitory concentration (IC50) valuesSeries vaccinationVaccine seriesVaccine regimensClinical factorsDiabetes mellitusRenal diseaseComorbid conditionsSteroid useCOVID infectionImmune responseUS population
2019
Native Joint Septic Arthritis: Comparison of Outcomes with Medical and Surgical Management.
Harada K, McConnell I, DeRycke EC, Holleck JL, Gupta S. Native Joint Septic Arthritis: Comparison of Outcomes with Medical and Surgical Management. Southern Medical Journal 2019, 112: 238-243. PMID: 30943544, DOI: 10.14423/smj.0000000000000958.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAnkle JointAnti-Bacterial AgentsArthritis, InfectiousArthrocentesisArthroscopyCandidiasisDrainageElbow JointFemaleGram-Negative Bacterial InfectionsGram-Positive Bacterial InfectionsHip JointHospitalizationHumansKnee JointMaleMiddle AgedRange of Motion, ArticularRecovery of FunctionRetrospective StudiesShoulder JointStaphylococcal InfectionsSternoclavicular JointStreptococcal InfectionsTertiary Care CentersWrist JointConceptsSeptic arthritisSurgical managementCases of SADiagnosis of SARetrospective single-center studyNative joint septic arthritisSingle-center studyTertiary care hospitalLong-term outcomesLength of stayShort-term rehabilitationComparison of outcomesNative joint infectionsCare hospitalMedical managementJoint infectionRehabilitation unitInclusion criteriaEvaluated outcomesNative jointProsthetic jointsFull recoveryPatientsOutcomesSame joint
2017
The “Hand-in” Project
Holleck JL, Gunderson CG, Antony SM, Gupta S, Chang JJ, Merchant N, Lin S, Federman DG. The “Hand-in” Project. Southern Medical Journal 2017, 110: 694-698. PMID: 29100218, DOI: 10.14423/smj.0000000000000724.Peer-Reviewed Original ResearchMeSH KeywordsAgedAmbulatory CareComputer SecurityContinuity of Patient CareElectronic MailEmergency Service, HospitalFemaleHospitalistsHospitalizationHumansInterprofessional RelationsMalePatient ReadmissionPhysicians, Primary CareProspective StudiesUnited StatesUnited States Department of Veterans Affairs
2016
Clinical characteristics and outcomes of veterans hospitalised with purulent soft tissue infections with and without systemic signs of infection
Gunderson CG, Holleck J, Chang JJ, Lin S, Merchant N, Gupta S. Clinical characteristics and outcomes of veterans hospitalised with purulent soft tissue infections with and without systemic signs of infection. Infectious Diseases 2016, 48: 503-508. PMID: 26950290, DOI: 10.3109/23744235.2016.1154599.Peer-Reviewed Original ResearchConceptsPurulent soft tissue infectionsSoft tissue infectionsTissue infectionsClinical characteristicsSevere sepsisSIRS groupSystemic signsSIR groupSystemic inflammatory response syndrome criteriaBroad Gram-negative activityMethods Retrospective cohort studyOutcomes of veteransAcute kidney injuryRetrospective cohort studyEpisodes of bacteremiaTime of hospitalisationCohort of patientsMajority of patientsMost clinical characteristicsUse of antibioticsMore bacteremiaKidney injuryShorter hospitalisationSyndrome criteriaCohort studyParvimonas micra: A rare cause of native joint septic arthritis
Baghban A, Gupta S. Parvimonas micra: A rare cause of native joint septic arthritis. Anaerobe 2016, 39: 26-27. PMID: 26911898, DOI: 10.1016/j.anaerobe.2016.02.004.Peer-Reviewed Case Reports and Technical NotesConceptsNative joint septic arthritisSeptic arthritisCases of discitisKnee septic arthritisSignificant joint destructionFrequent boneHematogenous seedingJoint destructionSubacute presentationRare causeDental proceduresPeriodontal diseaseParvimonas micraPeptostreptococcus microsGastrointestinal floraProsthetic jointsPositive cocciArthritisJoint pathogensOrganism identificationRRNA sequencingMicraAssociationLiterature reviewDiscitis
2009
Raltegravir With Unboosted Atazanavir 300 mg Twice Daily in Antiretroviral Treatment-Experienced Participants
Gupta S, Lataillade M, Farber S, Kozal MJ. Raltegravir With Unboosted Atazanavir 300 mg Twice Daily in Antiretroviral Treatment-Experienced Participants. Journal Of The International Association Of Providers Of AIDS Care (JIAPAC) 2009, 8: 87-92. PMID: 19270153, DOI: 10.1177/1545109709332471.Peer-Reviewed Original ResearchConceptsMean CD4 count increaseCD4 count increaseCombination of raltegravirTreatment-experienced patientsPotent antiretroviral activityCopies/mLProtease inhibitorsARV agentsUnboosted atazanavirHIV RNAImmunologic outcomesTwice DailyAntiretroviral treatmentARV therapyAntiretroviral agentsCase seriesHIV integrase inhibitorsTherapeutic failureAntiretroviral activityRaltegravirAtazanavirIntegrase inhibitorsAdverse effectsCells/Count increase
2008
Persistent and Relapsing Babesiosis in Immunocompromised Patients
Krause PJ, Gewurz BE, Hill D, Marty FM, Vannier E, Foppa IM, Furman RR, Neuhaus E, Skowron G, Gupta S, McCalla C, Pesanti EL, Young M, Heiman D, Hsue G, Gelfand JA, Wormser GP, Dickason J, Bia FJ, Hartman B, Telford SR, Christianson D, Dardick K, Coleman M, Girotto JE, Spielman A. Persistent and Relapsing Babesiosis in Immunocompromised Patients. Clinical Infectious Diseases 2008, 46: 370-376. PMID: 18181735, DOI: 10.1086/525852.Peer-Reviewed Original ResearchConceptsCase patientsAntibabesial treatmentClinical courseControl subjectsBlood smearsRetrospective case-control studyOptimal treatment regimenStandard antimicrobial therapyMalaria-like illnessBabesia microti infectionMost cases patientsCase-control studyCourse of therapyB-cell lymphomaAdministration of atovaquoneImmunologic statusStandard therapyAntimicrobial regimenSuch patientsTreatment regimenMicroti infectionAntimicrobial therapyPersistent infectionCell lymphomaAcute babesiosis